The science behind metastatic bone pain

European Journal of Cancer, Supplement

Volumn 4, Issue 8, 2006, Pages 4-8

  Mantyh, Patrick ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Bisphosphonates; Bone metastases; Cancer; Mouse model; Pain

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID; OPIATE; RECEPTOR;

ACIDITY; ARTICLE; BONE DESTRUCTION; BONE MARROW; BONE METASTASIS; BONE PAIN; CANCER PAIN; CANCER TRANSPLANTATION; CELL PROLIFERATION; FEMUR; MACROPHAGE; MONITORING; NERVE CELL; NERVE FIBER; NONHUMAN; OSTEOCLAST; OSTEOPOROSIS; OUTCOME ASSESSMENT; PALLIATIVE THERAPY; PH; PRIORITY JOURNAL; TUMOR CELL; TUMOR GROWTH;

EID: 33747341386     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcsup.2006.07.003     Document Type: Article

References (37)

1. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 69 1-2 (1997) 1-18
2. Bonica J.J. Management of cancer pain. Acta Anaesthesiol Scand Suppl 74 (1982) 75-82
3. Urch C. The pathophysiology of cancer-induced bone pain: current understanding. Palliat Med 18 4 (2004) 267-274
4. Mercadante S., and Arcuri E. Breakthrough pain in cancer patients: pathophysiology and treatment. Cancer Treat Rev 24 6 (1998) 425-432
5. Mercadante S., Radbruch L., Caraceni A., et al. Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer 94 3 (2002) 832-839
6. Zech D.F., Grond S., Lynch J., Hertel D., and Lehmann K.A. Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study. Pain 63 1 (1995) 65-76
7. Mercadante S., and Fulfaro F. World Health Organization guidelines for cancer pain: a reappraisal. Ann Oncol 16 Suppl. 4 (2005) iv132-iv135
8. Cherny N., Ripamonti C., Pereira J., et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 19 9 (2001) 2542-2554
9. McNicol E., Horowicz-Mehler N., Fisk R.A., et al. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain 4 5 (2003) 231-256
10. Mundy G.R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2 8 (2002) 584-593
11. Roodman G.D. Mechanisms of bone metastasis. N Engl J Med 350 16 (2004) 1655-1664
12. Coleman R.E., Major P., Lipton A., et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23 22 (2005) 4925-4935
13. Luger N.M., Mach D.B., Sevcik M.A., and Mantyh P.W. Bone cancer pain: from model to mechanism to therapy. J Pain Symptom Manage 29 Suppl. 5 (2005) S32-S46
14. Mantyh P.W., Clohisy D.R., Koltzenburg M., and Hunt S.P. Molecular mechanisms of cancer pain. Nat Rev Cancer 2 3 (2002) 201-209
15. Sabino M.A., and Mantyh P.W. Pathophysiology of bone cancer pain. J Support Oncol 3 1 (2005) 15-24
16. Luger N.M., Sabino M.A., Schwei M.J., et al. Efficacy of systemic morphine suggests a fundamental difference in the mechanisms that generate bone cancer vs inflammatory pain. Pain 99 3 (2002) 397-406
17. Sevcik M.A., Luger N.M., Mach D.B., et al. Bone cancer pain: the effects of the bisphosphonate alendronate on pain, skeletal remodeling, tumor growth and tumor necrosis. Pain 111 1-2 (2004) 169-180
18. Luger N.M., Honore P., Sabino M.A., et al. Osteoprotegerin diminishes advanced bone cancer pain. Cancer Res 61 10 (2001) 4038-4047
19. Honore P., Luger N.M., Sabino M.A., et al. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med 6 5 (2000) 521-528
20. Sabino M.A., Ghilardi J.R., Jongen J.L., et al. Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2. Cancer Res 62 24 (2002) 7343-7349
21. Conte P.F., Latreille J., Mauriac L., et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. J Clin Oncol 14 9 (1996) 2552-2559
22. Theriault R.L., Lipton A., Hortobagyi G.N., et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. J Clin Oncol 17 3 (1999) 846-854
23. Hortobagyi G.N., Theriault R.L., Lipton A., et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 16 6 (1998) 2038-2044
24. Kohno N., Aogi K., Minami H., et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 23 15 (2005) 3314-3321
25. Body J.J., Diel I.J., Lichinitser M.R., et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases (Corrigendum published in Ann Oncol 2004;15:180). Ann Oncol 14 9 (2003) 1399-1405
26. Body J.J., Diel I.J., Bell R., et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 111 3 (2004) 306-312
27. Diel I.J., Body J.J., Lichinitser M.R., et al. Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer 40 11 (2004) 1704-1712
28. Heidenreich A., Ohlmann C., Olbert P., and Hegele A. High-dose ibandronate is effective and well tolerated in the treatment of pain and hypercalcaemia due to metastatic urologic cancer. Eur J Cancer 1 Suppl. 5 (2003) S270 (abstract 897)
29. Mancini I., Dumon J.C., and Body J.J. Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study. J Clin Oncol 22 17 (2004) 3587-3592
30. Fromigue O., Lagneaux L., and Body J.J. Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 15 11 (2000) 2211-2221
31. Hiraga T., Williams P.J., Mundy G.R., and Yoneda T. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res 61 11 (2001) 4418-4424
32. Dumon J.C., Journe F., Kheddoumi N., Lagneaux L., and Body J.J. Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cells. Eur Urol 45 4 (2004) 521-528
33. van der Pluijm G., Vloedgraven H., van Beek E., van der Wee-Pals L., Lowik C., and Papapoulos S. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 98 3 (1996) 698-705
34. Boissier S., Magnetto S., Frappart L., et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 57 18 (1997) 3890-3894
35. Boissier S., Ferreras M., Peyruchaud O., et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 60 11 (2000) 2949-2954
36. Fournier P., Boissier S., Filleur S., et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62 22 (2002) 6538-6544
37. Schwei M.J., Honore P., Rogers S.D., et al. Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J Neurosci 19 24 (1999) 10886-10897